A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR

Similar documents
Prostate Overview Quiz

Interactive Discussion of Part I CS Coding Instructions: Working the Cases

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Testicular Malignancies /8/15

Genitourinary. Presentation Outline. Genitourinary System 12/14/2011. FCDS 2011 Educational Webcast Series December 15, 2011

Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Attachment #2 Overview of Follow-up

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Attachment #2 Overview of Follow-up

Coding Pitfalls 9/1/2011. Coding Pitfalls Questions. Fabulous Prizes!!! September 1, NAACCR Webinar Series 1

Quiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.

Change Log V1.3- v1.4

2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System

Prostate Case Scenario 1

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

Neoplasms of the Prostate and Bladder

Histology Coding ANSWERS

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Collaborative Stage Data Collection System (CSv xx) Reporting Requirements Commission on Cancer (CoC)

Prognostic factors of genitourinary tumors: Do we have to care?

AJCC 7th Edition Handbook Errata as of 9/21/10

NAACCR Webinar Series 1

GUIDELINES ON PROSTATE CANCER

Major Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging

Kentucky Cancer Registry Spring Training 2017

Collaborative Stage Data Collection System (CSv2) Reporting Requirements Commission on Cancer (CoC) (Updated 4/8/ changes in red print)

Collaborative Staging

2018 New Grade Coding Rules It s a Good Thing!

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

CS Evaluation Fields. Outline of Presentation. Purpose of Evaluation Field. CSv2 Title of Presentation Jan 2011 Lecture Version: 1.

Urology An introduction to cut up DR J R GOEPEL

Quiz. b. 4 High grade c. 9 Unknown

Instructions for Coding Grade for 2014+

6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR

Appendix H 2018 FCDS Required Site Specific Data Items (SSDIs)

-The cause of testicular neoplasms remains unknown

SEER Summary Stage Still Here!

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Vivien W. Chen, PhD Mei-Chin Hsieh, MSPH, CTR Lisa A. Pareti, BS, CTR Xiao-Cheng Wu, MD, MPH, CTR. NAACCR Conference Portland, Oregon, June 5-7, 2012

Coding Pitfalls 9/11/14

Boot Camp Case Scenarios

3. Guidelines for Reporting Bladder Cancer, Prostate Cancer and Renal Tumours

UK CAA Oncology Certification Charts

Male genital tract tumors. SiCA. Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital.

2018 New Required Data Items for Hospitals

CDC & Florida DOH Attribution

Cardiff MRCS OSCE Courses Testicular Cancer

Prostate Cancer Case Study 2. Medical Student Case-Based Learning

Exercise. Discharge Summary

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

Interactive Staging Bee

Coding Pitfalls 9/11/14

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Kidney, Bladder and Prostate Neoplasia. David Bingham MD

ADENOCARCINOMA OF THE PROSTATE

CDC & Florida DOH Attribution

Collecting Cancer Data: Testis 2/3/11. Collecting Cancer Data: NAACCR Webinar Series 1. Agenda. Fabulous Prizes

Note: The cause of testicular neoplasms remains unknown

Testis. Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies.

Doppler ultrasound of the abdomen and pelvis, and color Doppler

A patient with recurrent bladder cancer presents with the following history:

THE UROLOGY GROUP

Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data,

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules

3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships

FINALIZED SEER SINQ QUESTIONS April July, 2017

GUIDELINEs ON PROSTATE CANCER

International London Uropathology Conference 2014

MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

Introduction & Descriptors

Esophagus, Esophagus GE Junction, Stomach

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

Seventh Edition Staging 2017 Melanoma. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.

Automated Coding of Key Case Identifiers from Text-Based Electronic Pathology Reports

Update on Reporting Prostate Cancer Pathology

There is a Reason for Everything including Changes

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

Testicular leydig cell tumor with metachronous lesions: Outcomes after metastasis resection and cryoablation

Case Scenario 1: Breast

25 TH ICRO DEHRADUN STAGING OF GENITOURINARY MALIGNANCIES

What is Testicular cancer?

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

Coding Pitfalls 9/3/15

AQUA Registry 2019 Non-QPP Measure Specifications. Denominator Exceptions. IPSS<8 None None Yes Patient Reported Outcome (PRO)

Transcription:

A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR

Survey Questions and Answers 250 Responses 2

Question #1 A gentleman has a needle core biopsy on March 30, 2011. Which of the following PSA s would be recorded in SSF 1? 34.2 in November 2010 31.6 in January 2011 26.9 in March 22, 2011 3

#1 Answer Choices A. 34.2 B. 31.6 C. 26.9 D. Unknown 4

Survey Monkey Results Percentage 60 50 40 30 20 10 0 55.4 29.7 14.9 A B C D 0 5

Correct Answer and Rationale The correct answer is: B. 31.6 Per the coding instructions in CS, (Part I, Section II, v02.03, pg. 110), If more than one PSA test is given in the three months prior to treatment, record the highest value even if it is not the closest to initiation of treatment. PSA 34.2 is outside the three month window. 6 The PSA s from January and March are within the 3 month window and the 31.6 from January is the higher of the two.

Question #2 What are SSF 12 (Number of Cores Positive) and SSF 13 (Number of Cores Examined) based on the following? Specimen: Prostate, right base, right mid, right apex, left base, left mid, left apex Final Pathologic diagnosis: Benign prostatic tissue with mild chronic inflammation x 2 Benign prostatic tissue Adenocarcinoma, Gleason 7 (3+4), involving 10 to 50% of 3 cores Adenocarcinoma, Gleason 7 (3+4), involving 10 to 90% of 4 cores Adenocarcinoma, Gleason 7 (3+4), involving 10 to 20% of 2 cores 7

#2 Answer Choices A. SSF 12: 009, SSF 13: 009 B. SSF 12: 009, SSF 13: 012 C. SSF 12: 991, SSF 13: 991 D. SSF 12: 009, SSF 13: 991 8

Percentage 50 45 40 35 30 25 20 15 10 5 0 Survey Monkey Results 45.8 20.9 19.7 13.7 A B C D 9

Correct Answer and Rationale The correct answer is: D. SSF 12: 009, SSF 13: 991 Per the final pathology report, there are 9 positive cores. There were 6 total anatomic locations biopsied but the number of cores biopsied is not documented. Code 991, biopsy cores examined, number unknown, is coded for number of cores examined. 10

Question #3 Prostate case has two needle core biopsies taken. The first needle core biopsy shows Gleason score of 2+5=7. The second needle core biopsy shows Gleason score of 4+4=8. How do you code SSF 7? 11

#3 Answer Choices A. 052 B. 025 C. 044 D. 099 12

Percentage 100 90 80 70 60 50 40 30 20 10 0 Survey Monkey Results 98.4 0.8 0.8 A B C D 0 13

Correct Answer and Rationale The correct answer is: C. 044 Per the CS manual, you record the Gleason values with the highest score, which is the 4+4=8. 14

Question #4 A patient was diagnosed with prostate cancer. Due to other medical conditions, watchful waiting was chosen. Four months later, patient had a prostatectomy, which showed bilateral involvement of lobes with extracapsular extension invasion and margins. 15 How do you code SSF 3?

#4 Answer Choices A. 415 (Extension to periprostatic tissue: Extracapsular extension [beyond prostatic capsule], NOS; Through capsule NOS) B. 480 (Extracapsular extension and specific margins involved) C. 970 (No prostatectomy done within first course of treatment) 16 D. 980 (Prostatectomy performed, but not considered first course of treatment)

Percentage 50 45 40 35 30 25 20 15 10 5 0 Survey Monkey Results 45.4 33.7 15.3 5.6 A B C D 17

Correct Answer and Rationale The correct answer is: D. 980 First course of treatment was watchful waiting. Code 980 states that a prostatectomy was done, but not considered first course of treatment. 18

Question #5 A testicular cancer case has no orchiectomy. How should SSF s 6-10, which focus on preorchiectomy levels, be coded? 19

#5 Answer Choices A. 988 (Not applicable: Information not collected for this case) B. 996 (No orchiectomy performed, initial range recorded in post orchiectomy field) C. 998 (Test not done [test not ordered and not performed]) 20 D. 999 (Unknown or no information)

Survey Monkey Results Percentage 100 90 80 70 60 50 40 30 20 10 0 82.3 4 4.4 9.3 A B C D 21

Correct Answer and Rationale The correct answer is: B. 996 Per the CS manual, when an orchiectomy is not performed, use code 996 for SSF s 6-10. 22

Question #6 The testis schema requires collection of 3 different lab values to determine the S component of the staging. Which of the following 4 lab values is not part of the Testis schema? 23

#6 Answer Choices A. Alpha fetoprotein (AFP) B. Testosterone (T) C. Human chorionic gonadotropin (hcg) D. Lactate dehydrogenase (LDH) 24

Percentage 100 90 80 70 60 50 40 30 20 10 0 Survey Monkey Results 97.2 0.8 0.4 1.6 A B C D 25

Correct Answer and Rationale The correct answer is: B. Testosterone (T) Testosterone is not collected in the Testis schema. 26

Question #7 A patient was diagnosed via biopsy with testicular cancer. Part of his workup included the following serum tumor markers: AFP, hcg and LDH. Based on staging workup, chemotherapy was administered prior to orchiectomy. How should the tumor markers be documented? 27

#7 Answer Choices A. The ranges should be coded as unknown in SSF s 6-10 B. The range values should be coded in the preorchiectomy SSF s 6-10 C. The ranges should be coded as unknown in the post-orchiectomy SSF s 13, 15, 16 28 D. The range values should be coded in the postorchiectomy SSF s 13, 15, 16

Survey Monkey Results Percentage 60 50 40 30 20 53.4 41 10 0 2 3.6 A B C D 29

Correct Answer and Rationale The correct answer is: D. The range values should be coded in the post-orchiectomy SSF s 13, 15, 16 Per the CS manual For those cases where an orchiectomy is not performed or where the patient receives neoadjuvant therapy Code the initial lab value in the post orchiectomy SSF rather than the pre-orchiectomy SSF. 30

Question #8 A pathology report from a TURB for a papillary transitional cell bladder carcinoma states the tumor is a grade 2. How would you code SSF 1 for WHO/ISUP grade? 31

#8 Answer Choices A. 010 (Low grade urothelial carcinoma) B. 020 (High grade urothelial carcinoma) C. 988 (Not applicable: Information not collected for this case) D. 999 (Unknown WHO/ISUP grade) 32

Survey Monkey Results 80 70 69 Percentage 60 50 40 30 20 10 0 16.1 11.7 3.2 A B C D 33

Correct Answer and Rationale The correct answer is: D. 999 The pathology does not indicate that this is a WHO/ISUP grade. When only the grade (2) is stated, cannot assume that it s a WHO/ISUP grade. Code 999 for unknown. 34

Question #9 A patient has a nephrectomy with 12 lymph nodes removed with 6 positive. There is no mention of extracapsular extension. How do you code SSF 8? 35

#9 Answer Choices A. 000 (No regional lymph nodes involved) B. 010 (Extranodal extension not present; regional nodes described as mobile) C. 030 (Regional nodes involved, unknown if extranodal extension) 36 D. 999 (Unknown; regional lymph nodes not stated)

Survey Monkey Results 70 60 57.8 Percentage 50 40 30 20 10 0 39.4 1.2 1.6 A B C D 37

Correct Answer and Rationale The correct answer is: B. 010 Code 010 when there is a pathology report with involved nodes but there is no mention of extranodal extension. 38

Question #10 A nephrectomy is performed for a renal cell carcinoma. There is no mention of tumor necrosis in the pathology report. How do you code SSF 5? 39

#10 Answer Choices A. 000 (Histologic tumor necrosis not present/ not identified) B. 010 (Histologic tumor necrosis present/ identified) C. 988 (Not applicable: Information not collected for this case) 40 D. 999 (Unknown or no information)

Survey Monkey Results Percentage 100 90 80 70 60 50 40 30 20 10 0 86.3 9.6 1.6 2.4 A B C D 41

Correct Answer and Rationale The correct answer is: A. 000 Code 000 can be used when there is a pathology report and there is no mention of tumor necrosis. 42

CAnswer Forum Submit questions to CS Forum Located within the CAnswer Forum Provides information for all Allows tracking for educational purposes Includes archives of Inquiry & Response System 43 http://cancerbulletin.facs.org/forums/